Anti-PD-L1 antibodiesAspects of the invention include isolated anti-PD-L1 antibodies, as well as compositions containing such antibodies, and methods of using the same in the treatment of diseases or conditions that are mediated by PD-L1 signaling.Keyt Bruce...
Anti-PD-L1 antibodies are disclosed. Also disclosed are pharmaceutical compositions comprising such antibodies, and methods of using such antibodies to restore T-cell function in T-cells exhibiting T-cell exhaustion or T-cell anergy.Wang, Cheng-iOh, Hsueh Ling JaniceYeo, Siok Ping...
The use of monoclonal antibodies directed against the antigen-experienced T-cell marker programmed cell death 1 (PD-1) and its ligand PD-L1 in the context of chronic infectious diseases is reviewed. The potential pitfalls and precautions, based on clinical experience from treating patients with can...
Anti-PD-1/PD-L1 antibodies showed satisfactory efficacy in treating non-small-cell lung cancer. We conducted this meta-analysis to explore the advantage subtypes and best therapeutic modalities of Anti-PD-1/PD-L1 therapy on NSCLC. A quantitative meta-analysis was performed through a systematic se...
In 2016 and 2017, monoclonal antibodies targeting PD-L1, including atezolizumab, durvalumab, and avelumab, were approved by the FDA for the treatment of multiple advanced cancers. And many other anti-PD-L1 antibodies are under clinical trials. Recently,
Disclosed are an anti-PD-L1 antibody or an antigen-binding fragment thereof, a nucleic acid encoding the same, a vector including the nucleic acid, a cell transformed with the vecto
Lung cancer remains a leading cause of cancer-related mortality worldwide with the poor prognosis. Encouragingly, immune checkpoint blockade targeting programmed death-1 (PD-1) and programmed death-l...
Tumor extracellular matrix has been associated with drug resistance and immune suppression. Here, proteomic and RNA profiling reveal increased collagen levels in lung tumors resistant to PD-1/PD-L1 blockade. Additionally, elevated collagen correlates wit
InvivoGen offers twomurinizedmonoclonal antibodies (mAb) targeting PD-L1 (programmed cell death ligand 1), and therefore blocking the interaction with its receptor PD-1: Anti-PD-L1-mIgG1e3 (10F.9G2) InvivoFit™ features the variable region of the rat-derived clone 10F.9G2, targeting mo...
背景[1-3] ANTI-PD-L1抗体是一类可以特异性结合PD-L1的多克隆抗体,主要用于检测PD-L1的Western Blot、IHC-P、IF、ELISA、Co-IP等多种免疫学实验。 检测原理:双抗体夹心法测定标本中PD-L1水平。用纯化的PD-L1抗体包被微孔板,制成固相抗体,往包被单抗的微孔中依次加入PD-L1,再与HRP标记的PD-L1抗体结合,形成...